
ADVERTISING MEDICINAL PRODUCTS IN THE INTERIM PERIOD BETWEEN MARKETING AUTHORISATION AND THE DECISION ON PRICING AND PUBLIC FUNDING
This paper analyses the promotion of medicines for human use that have already received marketing authorization, when the advertising is made before the resolution on pricing and inclusion in the Spanish National Health Service. This is an issue addressed by